Carrelizumab neoadjuvant treatment of locally advanced esophageal squamous cell carcinoma research results presented at the annual meeting of the Chinese Society of Clinical Oncology

Shanghai, September 30, 2021/PRNewswire/ - September 29, at the 24th National Conference on Clinical Oncology and the 2021 CSCO Annual Conference, Carrelizumab combined with paclitaxel and nedaplatin The results of a single-arm, open, phase II exploratory study (ESPRIT study) of neoadjuvant treatment of locally advanced esophageal squamous cell carcinoma stood out from 1470 submitted papers and were included in the oral report of the conference

Esophageal cancer is a tumor with "Chinese characteristics", and new cases and deaths each year account for more than half of the global cases [1]

The phased data of the ESPRIT study shows that for patients with locally advanced resectable esophageal cancer, the "neoadjuvant immune combined with chemotherapy" treatment mode can bring good disease relief to patients, with an objective remission rate of 50% and approximately 56% of patients After the completion of neoadjuvant therapy, downtime can be achieved

Professor Ma Jianqun pointed out in his oral report: “The results of the ESPRIT study suggest that carrelizumab combined with paclitaxel and nedaplatin neoadjuvant treatment of locally advanced esophageal squamous cell carcinoma can achieve tumor shrinkage and complete down-stage, which will bring good benefits to patients.

This cutting-edge research is of great significance for prolonging the survival time of patients and improving the prognosis of patients

Carrelizumab is independently developed by Jiangsu Hengrui Pharmaceutical Co.

references:

[1].

[2].

[3].

[4].

[5].

Source: Jiangsu Hengrui Pharmaceutical Co.